SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Arbutus Biopharma Corporation (ABUS)

Add ABUS Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board:
Last Post: 10/22/2016 3:33:08 PM - Followers: 101 - Board type: Free - Posts Today: 4

Arbutus Biopharma Corporation







Company Information:

100 - 8900 Glenlyon Parkway
Burnaby, British Columbia
Canada V5J 5J8

Telephone: 604.419.3200
Fax: 604.419.3201


As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.

 Tekmira is uniquely equipped to become a leading force in the field. Guided by a cohesive vision, the company possesses leading technology capabilities and a solid intellectual property portfolio in the area of lipid-based nucleic acid delivery, known as SNALP (Stable Nucleic Acid Lipid Particles) to deliver siRNAs (small interfering RNAs) as well as other oligonucleotides in the treatment of disease.

With one RNAi drug candidate in clinical development and another in late preclinical development,  plus a pipeline of up to five additional targets made possible through an agreement with RNAi leader Alnylam, Tekmira is well positioned to aggressively advance its product development strategy. In addition to Alnylam, Roche, Merck and Regulus all have access to Tekmira's technology in the delivery of siRNAs and microRNAs.

Finally, broad manufacturing capabilities and a strong capital position permit the company to move forward decisively and build a solid base for both near and longer term growth.




Important Company Highlights: 

LNP Delivery Platform

Tekmira’s Lipid Nanoparticle (LNP) technology represents the most widely adopted RNAi delivery technology to date. Administered intravenously, our LNP delivery technology allows RNAi drugs to be encapsulated in tiny particles made of lipids (fats or oils). These tiny particles – LNP – travel through the bloodstream to target tissues.





Recent News:





Links of importance for those that trade Canadian stocks:




 CNW Group Newswire:

Canadian Insider:

Currency Converter:


Transfer Agent:

CIBC Mellon Trust,
Suite 1600, The Oceanic Plaza,
1066 West Hastings Street,
Vancouver, BC V6E 3X1

Share Structure:   See filings

Investor Relations:

Ian Mortimer
Executive Vice President, Finance and Chief Financial Officer
Telephone: 604.419.3200
Fax: 604.419.3201

Adam Peeler
Investor Relations
The Equicom Group
Telephone: 416.815.0700 x 225 

 Currency Converter:


 8-34-200/ 6 MOS ppo, accum.,R.S.I., PPS, vol 

daily retracement % 
18 mos, black, daily, retrace 3%, pos retrace 5%, retrace 7%, volume, candles, pps, 






 All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn't a sign of endorsement.

 Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ABUS News: Amended Statement of Beneficial Ownership (sc 13d/a) 10/19/2016 04:28:06 PM
ABUS News: Statement of Beneficial Ownership (sc 13d) 10/19/2016 04:14:45 PM
ABUS News: Initial Statement of Beneficial Ownership (3) 10/19/2016 04:12:34 PM
ABUS News: Patrick Machado Joins Board of Directors of Roivant Sciences 10/19/2016 04:01:00 PM
ABUS News: Statement of Changes in Beneficial Ownership (4) 10/06/2016 01:48:50 PM
#4953  Sticky Note NEW COMPANY NAME/ ARBUTUS BIOPHARMA CORPORATION/ $ABUS recent news/filings[/b mick 08/06/15 01:42:07 PM
#5094   ABUS News: Amended Statement of Beneficial Ownership (sc mick 10/22/16 03:33:08 PM
#5093   Arbutus Biopharma Co (ABUS) mick 10/22/16 03:32:55 PM
#5092   could be huge gainer with nlnk partner. 'Arbutus mick 10/22/16 03:17:18 PM
#5091   $ABUS Daily Chart $Pistol Pete$ 10/22/16 01:47:32 PM
#5090   ABUS News: Statement of Changes in Beneficial Ownership mick 10/16/16 10:21:49 PM
#5089   Arbutus Biopharma Co (ABUS) mick 10/16/16 10:21:43 PM
#5088   Short int isn't much at all but there rivervalley 10/12/16 07:47:39 PM
#5087   Too early. They fired 2 main people after md3423 10/12/16 01:55:17 PM
#5086   Perhaps an early tax loss selling. bernice 10/12/16 01:36:17 PM
#5085   Something not right, looks like they're tanking this, md3423 10/12/16 01:30:19 PM
#5084   ABUS News: Current Report Filing (8-k) 09/29/2016 04:02:28 PM mick 10/01/16 11:47:25 AM
#5083   Arbutus Biopharma Co (ABUS) mick 10/01/16 11:47:19 AM
#5082   It did rise nicely at first ah yesterday rivervalley 09/30/16 12:34:01 PM
#5081   Surprised we haven't seen a rise given the md3423 09/30/16 11:09:46 AM
#5080   Not much vol at all in pm,so far rivervalley 09/30/16 09:26:58 AM
#5079   I've averaged down more times on this one rivervalley 09/29/16 07:22:50 PM
#5078   Arbutus Reports Interim Multi-Dose Results from Phase II KarinCA 09/29/16 06:48:12 PM
#5077   Moves up over $1 in ah session then rivervalley 09/29/16 06:29:33 PM
#5076   Let's see if she can move above and rivervalley 09/26/16 02:58:25 PM
#5075   ABUS News: Current Report Filing (8-k) 09/13/2016 07:01:03 AM mick 09/18/16 01:44:34 PM
#5074   Arbutus Biopharma Co (ABUS) mick 09/18/16 01:44:28 PM
#5073   ABUS News: Current Report Filing (8-k) 08/19/2016 02:24:40 PM mick 09/04/16 04:10:07 PM
#5072   Arbutus Biopharma Co (ABUS) mick 09/04/16 04:09:46 PM
#5071   Had this one for nearly a yr and rivervalley 08/19/16 03:45:42 PM
#5070   ABUS News: Current Report Filing (8-k) 08/10/2016 08:01:48 AM mick 08/14/16 12:34:49 PM
#5069   Arbutus Biopharma Co (ABUS) mick 08/14/16 12:34:29 PM
#5068   United States Patent 9,404,127 ubernano 08/08/16 04:45:06 PM
#5067   Green so far today and on low vol. rivervalley 08/03/16 03:12:21 PM
#5066   ABUS News: Current Report Filing (8-k) 07/19/2016 05:01:30 PM mick 07/24/16 03:01:16 PM
#5065   Arbutus Biopharma Co (ABUS) mick 07/24/16 03:01:11 PM
#5064   True, imho until september before volume and confidence Dr_Thorfin 07/21/16 04:54:20 PM
#5063   The last yr has been pretty tough for rivervalley 07/21/16 04:37:28 PM
#5062   Same at progenics, yesterday fda approved product with Dr_Thorfin 07/21/16 02:15:42 PM
#5061   Totally agree. Its depressing how uninterested traders seem rivervalley 07/21/16 01:49:03 PM
#5060   Pretty lame run after positive phase I & Dr_Thorfin 07/21/16 01:42:28 PM
#5059   Hopefully tomorrow this gets a nice boost after rivervalley 07/19/16 06:48:07 PM
#5058   News out ! ! ! Arbutus today reported the Dr_Thorfin 07/19/16 05:43:11 PM
#5057   Great day for ABUS, and here's hoping for rivervalley 07/01/16 06:17:23 PM
#5056   Held up well today compared to many other rivervalley 06/27/16 06:32:33 PM
#5055 mick 06/27/16 01:41:24 PM
#5054   Well the latest co update yesterday is doing rivervalley 06/10/16 02:49:33 PM
#5053   Nano Couple of days? Echo 20 Echo20 06/10/16 11:03:09 AM
#5052   Nano patent Ot: The court case against CTIX has Echo20 06/08/16 02:53:42 PM
#5051   12 results found in the Worldwide database for: ubernano 06/08/16 01:04:58 PM
#5050   Arbutus Biopharma Co (ABUS) mick 06/01/16 12:39:38 AM
#5048   ABUS News: Current Report Filing (8-k) 05/25/2016 02:09:50 PM mick 05/30/16 12:02:51 AM
#5047   Arbutus Biopharma Co (ABUS) mick 05/30/16 12:02:44 AM
#5046   ABUS News: Quarterly Report (10-q) 05/04/2016 04:12:59 PM mick 05/21/16 11:10:40 PM
#5045   Arbutus Biopharma Co (ABUS) mick 05/21/16 11:10:27 PM